Débora S. Bruno
University Hospitals of Cleveland · 95 works · 5,586 citations · h-index 20
Top works
- Non–Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 1.2020
- NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021
- Non–Small Cell Lung Cancer, Version 4.2024
- NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023
- Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
- Disparities in Biomarker Testing and Clinical Trial Enrollment Among Patients With Lung, Breast, or Colorectal Cancers in the United States
- Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).
- Impact of bariatric surgery on cancer risk reduction
- Pembrolizumab-Induced Immune-Mediated Colitis in a Patient with Concurrent Clostridium Difficile Infection
- Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1.
- Sex Differences in Lung Cancer Treatment and Outcomes at a Large Hybrid Academic-Community Practice
- Mesothelioma: Peritoneal, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology
- Acute Hypotensive Transfusion Reactions
- Mesothelioma: Pleural, Version 1.2024
- Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
- Next Generation Sequencing of Advanced Non–Small Cell Lung Cancer: Utilization Based on Race and Impact on Survival
- MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy
- Immunotherapy in EGFR mutant non-small cell lung cancer: when, who and how?
- ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.